KR20010041812A - 비트로넥틴 수용체 길항제 - Google Patents

비트로넥틴 수용체 길항제 Download PDF

Info

Publication number
KR20010041812A
KR20010041812A KR1020007010091A KR20007010091A KR20010041812A KR 20010041812 A KR20010041812 A KR 20010041812A KR 1020007010091 A KR1020007010091 A KR 1020007010091A KR 20007010091 A KR20007010091 A KR 20007010091A KR 20010041812 A KR20010041812 A KR 20010041812A
Authority
KR
South Korea
Prior art keywords
alkyl
phenyl
pyridin
mmole
compound
Prior art date
Application number
KR1020007010091A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 에이치. 밀러
존 지. 글리슨
더크 히어딩
제임스 엠. 사마넨
아이린 엔. 우진스카스
피터 제이. 맨리
Original Assignee
스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스
스미스클라인 비참 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스, 스미스클라인 비참 코포레이션 filed Critical 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스
Publication of KR20010041812A publication Critical patent/KR20010041812A/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020007010091A 1998-03-10 1999-03-10 비트로넥틴 수용체 길항제 KR20010041812A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7761098P 1998-03-10 1998-03-10
US60/077,610 1998-03-10
US9606398P 1998-08-11 1998-08-11
US60/096,063 1998-08-11
PCT/US1999/005232 WO1999045927A1 (en) 1998-03-10 1999-03-10 Vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
KR20010041812A true KR20010041812A (ko) 2001-05-25

Family

ID=26759473

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007010091A KR20010041812A (ko) 1998-03-10 1999-03-10 비트로넥틴 수용체 길항제

Country Status (24)

Country Link
EP (1) EP1061921A4 (es)
JP (1) JP2002506033A (es)
KR (1) KR20010041812A (es)
CN (1) CN1299282A (es)
AP (1) AP2000001898A0 (es)
AR (1) AR015241A1 (es)
AU (1) AU758498B2 (es)
BG (1) BG104824A (es)
BR (1) BR9908636A (es)
CA (1) CA2323208A1 (es)
CO (1) CO5080762A1 (es)
DZ (1) DZ2741A1 (es)
EA (1) EA200000921A1 (es)
HU (1) HUP0101143A3 (es)
ID (1) ID26223A (es)
IL (1) IL138245A0 (es)
NO (1) NO20004503L (es)
OA (1) OA12189A (es)
PE (1) PE20000323A1 (es)
PL (1) PL342881A1 (es)
SK (1) SK13292000A3 (es)
TR (1) TR200002625T2 (es)
UY (2) UY25421A1 (es)
WO (1) WO1999045927A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19939980A1 (de) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitoren des Integrins alphavbeta¶3¶
DE19939981A1 (de) * 1999-08-24 2001-03-01 Merck Patent Gmbh Neue Inhibitoren des Integrins alphavß3
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
AU2001269821A1 (en) 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US20070275956A1 (en) * 2003-10-14 2007-11-29 Lohray Braj B Novel Heterocyclic Compounds
CA2556944C (en) * 2004-03-05 2012-10-09 Taisho Pharmaceutical Co., Ltd. Thiazole derivative
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2006240423A1 (en) 2005-04-20 2006-11-02 Janssen Pharmaceutica, N.V. Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls
PL3040329T3 (pl) 2013-08-29 2019-04-30 Kyoto Pharma Ind Związek aromatyczny i jego zastosowanie w leczeniu chorób związanych z metabolizmem kości
JP6215335B2 (ja) 2013-09-24 2017-10-18 富士フイルム株式会社 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125034A0 (en) * 1995-12-29 1999-01-26 Smithkline Beecham Corp Vitronectin receptor antagonists
TR199801254T2 (xx) * 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r� antagonistleri.

Also Published As

Publication number Publication date
BR9908636A (pt) 2002-01-08
TR200002625T2 (tr) 2000-12-21
UY25519A1 (es) 1999-12-13
DZ2741A1 (fr) 2003-09-08
JP2002506033A (ja) 2002-02-26
NO20004503D0 (no) 2000-09-08
BG104824A (en) 2001-05-31
HUP0101143A2 (hu) 2001-08-28
HUP0101143A3 (en) 2002-12-28
CN1299282A (zh) 2001-06-13
CO5080762A1 (es) 2001-09-25
AU2903399A (en) 1999-09-27
WO1999045927A1 (en) 1999-09-16
PE20000323A1 (es) 2000-05-24
PL342881A1 (en) 2001-07-16
ID26223A (id) 2000-12-07
CA2323208A1 (en) 1999-09-16
OA12189A (en) 2006-05-09
SK13292000A3 (sk) 2001-06-11
AR015241A1 (es) 2001-04-18
EA200000921A1 (ru) 2001-04-23
NO20004503L (no) 2000-10-10
EP1061921A4 (en) 2005-03-30
EP1061921A1 (en) 2000-12-27
AU758498B2 (en) 2003-03-20
IL138245A0 (en) 2001-10-31
UY25421A1 (es) 2001-07-31
AP2000001898A0 (en) 2000-09-30

Similar Documents

Publication Publication Date Title
KR100589578B1 (ko) 비트로넥틴 수용기 길항제
KR20010041812A (ko) 비트로넥틴 수용체 길항제
US6855722B2 (en) Substituted indoles and their use as integrin antagonists
JP2001509166A (ja) 糖尿病および肥満の治療のためのβ▲下3▼作動薬としてのチアゾールベンゼンスルホンアミド
KR100620485B1 (ko) 비트로넥틴 수용체 길항제
JP4685307B2 (ja) ビトロネクチン受容体アンタゴニスト
JP5149794B2 (ja) 飽和リンカー基を含有するヘテロアリール置換アミドおよび医薬としてのその使用
US6458814B1 (en) Vitronectin receptor antagonists
US6881736B1 (en) Vitronectin receptor antagonists
US20020147334A1 (en) Vitronectin Receptor Antagonists
CZ20003289A3 (cs) Antagonisté receptoru vitronektinu
MXPA00008847A (es) Antagonistas de receptor de vitronectina

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid